Skip to main content

Market Overview

Recap: Syros Pharmaceuticals Q4 Earnings



Shares of Syros Pharmaceuticals (NASDAQ:SYRS) rose 2.2% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 34.78% over the past year to ($0.62), which missed the estimate of ($0.50).

Revenue of $5,698,000 up by 1021.65% year over year, which beat the estimate of $2,700,000.


Earnings guidance hasn't been issued by the company for now.

Syros Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Mar 04, 2021

Time: 08:30 AM

ET Webcast URL:


Company's 52-week high was at $15.65

Company's 52-week low was at $4.26

Price action over last quarter: Up 0.71%

Company Profile

Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is primarily involved in the segments of the pharmaceutical, biotechnology and other related markets that address gene control and cancer. The Company operates only in the United States.


Related Articles (SYRS)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at